Drugs / pIL-12
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02531425 | Sep 2015 → Jul 2018 | triple-negative breast carcinoma | OncoSec Medical Incorporated | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02493361 | Aug 2015 → Apr 2018 | melanoma | University of California, San Francisco | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pIL-12 | “Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions” NCT02531425 ↗ |
| Modality | Other / unclassified | “plasmids encoding IL-12” PMID 34754076 ↗ Nov 2021 |
| Route | Other | “pIL-12: 1/4 tumor volume at concentration of 0.5 mg/mL intratumoral, Days 1, 5, and 8 of each odd cycle” NCT02493361 ↗ |